Literature DB >> 14559317

Decreased oxidative stress in patients with ulcerative colitis supplemented with fish oil omega-3 fatty acids.

Décio Sabbatini Barbosa1, Rubens Cecchini, Mirian Zebian El Kadri, Maria Aparecida Marchesan Rodríguez, Roberto Carlos Burini, Isaias Dichi.   

Abstract

OBJECTIVE: The potential pathogenicity of free radicals may have a pivotal role in ulcerative colitis. Fish oil omega-3 fatty acids exert anti-inflammatory effects on patients with ulcerative colitis (UC), but the precise mechanism of the action of fish oil on oxidative stress is still controversial. The aim of the present work was to verify the blood oxidative stress in patients with UC and determine whether the association of sulfasalazine to fish oil omega-3 fatty acids is more effective than isolated use of sulfasalazine to reduce the oxidative stress.
METHODS: Nine patients (seven female and two male; mean age = 40 +/- 11 y) with mild or moderate active UC were studied in a randomized crossover design. In addition to their usual medication (2 g/d of sulfasalazine), they received fish oil omega-3 fatty acids (4.5 g/d) or placebo for 2-mo treatment periods that were separated by 2 mo, when they only received sulfasalazine. Nine healthy individuals served as control subjects to study the oxidative stress status. Disease activity was assessed by laboratory indicators (C-reactive protein, alpha1-acid glycoprotein, alpha1-antitrypsin, erythrocyte sedimentation rate, albumin, hemoglobin, and platelet count), sigmoidoscopy, and histology scores. Analysis of oxidative stress was assessed by plasma chemiluminescence and erythrocyte lipid peroxidation, both induced by tert butyl hydroperoxide (t-BuOOH) and by plasma malondialdehyde. Antioxidant status was assayed by total plasma antioxidant capacity (TRAP) and microsomal lipid peroxidation inhibition (LPI). Superoxide dismutase (SOD) and catalase erythrocyte enzymatic activities were also determined.
RESULTS: No significant changes were observed in any laboratory indicator or in the sigmoidoscopy or histology scores, with the exception of erythrocyte sedimentation rate, which decreased with both treatments. Oxidative stress was demonstrated by significant decreases in TRAP and LPI levels, increased chemiluminescence induced by t-BuOOH, and higher SOD activity in patients with UC. Treatment with fish oil omega-3 fatty acids reverted the chemiluminescence induced by t-BuOOH and LPI to baseline levels but that did not occur when patients received only sulfasalazine. Levels of plasma malondialdehyde, erythrocyte lipid peroxidation, and catalase were not different from those in the control group.
CONCLUSIONS: The results indicated that plasma oxidative stress occurs in patients with UC, and there was a significant decrease when the patients used sulfasalazine plus fish oil omega-3 fatty acids. However, there was no improvement in most laboratory indicators, sigmoidoscopy, and histology scores. The results suggested that omega-3 fatty acids may act as free radical scavengers protecting the patients against the overall effect of oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14559317     DOI: 10.1016/s0899-9007(03)00162-x

Source DB:  PubMed          Journal:  Nutrition        ISSN: 0899-9007            Impact factor:   4.008


  47 in total

1.  Benefits of omega-3 Fatty acids supplementation on serum paraoxonase 1 activity and lipids ratios in polycystic ovary syndrome.

Authors:  Elahe Mohammadi; Maryam Rafraf
Journal:  Health Promot Perspect       Date:  2012-12-28

2.  Fish oil supplementation decreases oxidative stress but does not affect platelet-activating factor bioactivity in lungs of asthmatic rats.

Authors:  A L Zanatta; D T S Z Miranda; B C L Dias; R M Campos; M C Massaro; P V Michelotto; A L West; E A Miles; P C Calder; A Nishiyama
Journal:  Lipids       Date:  2014-05-25       Impact factor: 1.880

Review 3.  Mitoxosome: a mitochondrial platform for cross-talk between cellular stress and antiviral signaling.

Authors:  Michal Caspi Tal; Akiko Iwasaki
Journal:  Immunol Rev       Date:  2011-09       Impact factor: 12.988

4.  Protective effects of 3,4-oxo-isopropylidene-shikimic acid on experimental colitis induced by trinitrobenzenesulfonic acid in rats.

Authors:  Jian-Feng Xing; Jian-Ning Sun; Jin-Yao Sun; Cui-Yu You; Kai Dong; Jun Lv; Ya-Lin Dong
Journal:  Dig Dis Sci       Date:  2012-04-03       Impact factor: 3.199

Review 5.  Inorganic nitrite therapy: historical perspective and future directions.

Authors:  Christopher G Kevil; Gopi K Kolluru; Christopher B Pattillo; Tony Giordano
Journal:  Free Radic Biol Med       Date:  2011-05-04       Impact factor: 7.376

6.  Antioxidant Supplements and Gastrointestinal Diseases: A Critical Appraisal.

Authors:  Islam Khan; Sue E Samson; Ashok Kumar Grover
Journal:  Med Princ Pract       Date:  2017-03-08       Impact factor: 1.927

7.  NCB-02 (standardized Curcumin preparation) protects dinitrochlorobenzene- induced colitis through down-regulation of NFkappa-B and iNOS.

Authors:  M V Venkataranganna; Md Rafiq; S Gopumadhavan; Ghouse Peer; U V Babu; S K Mitra
Journal:  World J Gastroenterol       Date:  2007-02-21       Impact factor: 5.742

8.  Decreased total and corrected antioxidant capacity in patients with inflammatory bowel disease.

Authors:  Ioannis E Koutroubakis; Niki Malliaraki; Philippos D Dimoulios; Konstantinos Karmiris; Elias Castanas; Elias A Kouroumalis
Journal:  Dig Dis Sci       Date:  2004-09       Impact factor: 3.199

9.  Restorative proctocolectomy for ulcerative colitis: impact on lipid metabolism and adipose tissue and serum fatty acids.

Authors:  Marco Scarpa; Giovanna Romanato; Enzo Manzato; Cesare Ruffolo; Raffaella Marin; Silvia Basato; Sabina Zambon; Teresa Filosa; Silvia Zanoni; Fabio Pilon; Lino Polese; Giacomo C Sturniolo; Davide F D'Amico; Imerio Angriman
Journal:  J Gastrointest Surg       Date:  2007-10-23       Impact factor: 3.452

Review 10.  Is there a role for fish oil in inflammatory bowel disease?

Authors:  Affifa Farrukh; John Francis Mayberry
Journal:  World J Clin Cases       Date:  2014-07-16       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.